Hematology

Standard of Care Treatment for Systemic Mastocytosis

At a Glance

Standard treatment for systemic mastocytosis (SM) involves symptom management with antihistamines and mast cell stabilizers, plus targeted therapies like avapritinib to block the KIT D816V mutation. All SM patients must carry two epinephrine auto-injectors at all times due to anaphylaxis risk.

Treatment for systemic mastocytosis (SM) has evolved into two distinct strategies: managing the chemicals released by mast cells (symptom management) and reducing the number of abnormal mast cells in the body (disease modification) ^[1]^[2]. Your care team will tailor your treatment plan based on your subtype and the severity of your symptoms.

Emergency Safety Protocol: Epinephrine

Because all SM patients have hyper-reactive mast cells, the risk for sudden, life-threatening allergic reactions (anaphylaxis) is high ^[3].

Universally Mandated Standard of Care: It is critical that all patients with SM carry two epinephrine auto-injectors (e.g., EpiPen) at all times and be fully trained in how and when to use them ^[4]. Never leave home without them.

Strategy 1: Symptom Management (Anti-Mediator Therapy)

For patients with Indolent Systemic Mastocytosis (ISM), the primary goal is to control the “leakage” of chemicals like histamine that cause flushing, abdominal pain, and allergic reactions ^[4]. This strategy does not cure the disease, but it aims to restore a normal quality of life.

Antihistamines: A combination of H1 blockers (like cetirizine or loratadine) and H2 blockers (like famotidine) is the first line of defense to block the effects of histamine ^[4]^[5].
Mast Cell Stabilizers: Cromolyn sodium is frequently used to treat gastrointestinal symptoms like diarrhea and cramping by making mast cells less likely to release their contents ^[6]^[4].
Leukotriene Antagonists: Medications like montelukast can help with respiratory symptoms or skin reactions ^[4].
Biologics (Omalizumab): If symptoms remain severe or if you experience recurrent anaphylaxis, your doctor may prescribe omalizumab ^[7]^[8].

Strategy 2: Disease-Modifying (Targeted) Therapy

When the disease is more aggressive or when symptoms cannot be controlled by standard medications, doctors use therapies that directly target the KIT D816V mutation—the biological “always on” switch of the disease ^[2]^[9].

Avapritinib: This is a highly selective KIT inhibitor approved for both advanced forms of SM and for adults with indolent SM who have severe symptoms ^[9]^[10]. It is specifically designed to bind to the mutant KIT protein and turn it off ^[11].
Midostaurin: This was the first targeted therapy approved for Advanced Systemic Mastocytosis (AdvSM). It is a multi-kinase inhibitor that helps reduce the number of mast cells and can improve organ function ^[12]^[13].

When is a Bone Marrow Transplant Considered?

Hematopoietic Stem Cell Transplantation (HSCT) is currently the only potentially curative treatment for systemic mastocytosis ^[14]. However, because it is a high-risk procedure, it is generally reserved for patients with the most aggressive forms of the disease, such as:

SM with an Associated Hematologic Neoplasm (SM-AHN) ^[14]^[15]
Mast Cell Leukemia (MCL) ^[12]

Important Monitoring: Bone Health

Bone health is a critical concern for SM patients. Mast cells can cause bone density loss, leading to osteoporosis and fractures, even in non-advanced, indolent forms of the disease ^[16]. Standard care involves getting a baseline DEXA scan to monitor bone density and discussing bone-strengthening treatments (like bisphosphonates) with your doctor if necessary ^[17]^[18].

Common questions in this guide

What is the emergency safety protocol for systemic mastocytosis?

All patients with systemic mastocytosis are at high risk for sudden, severe allergic reactions. It is a universal standard of care to carry two epinephrine auto-injectors at all times and know exactly how to use them in an emergency.

How are symptoms managed in indolent systemic mastocytosis?

Symptom management focuses on blocking chemicals like histamine using H1 and H2 blockers. Doctors may also prescribe mast cell stabilizers for gastrointestinal issues or biologics like omalizumab for severe allergic reactions.

What are targeted therapies for systemic mastocytosis?

Targeted therapies are disease-modifying drugs like avapritinib and midostaurin that specifically block the KIT D816V mutation. This mutation acts as the biological switch driving the disease, and blocking it helps reduce the number of abnormal mast cells.

When is a bone marrow transplant considered for systemic mastocytosis?

Stem cell transplantation is a high-risk procedure generally reserved for the most aggressive forms of the disease. This includes systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) or mast cell leukemia (MCL).

Why do systemic mastocytosis patients need bone density scans?

Mast cells can cause rapid bone density loss, leading to osteoporosis and bone fractures even in mild forms of the disease. Patients typically need baseline DEXA scans and may require bone-strengthening treatments like bisphosphonates.

Curated prompts to bring to your next appointment.

1.Given my specific subtype and symptoms, should our priority be symptom control or disease modification?
2.Are my current mediator-related symptoms (like flushing or GI distress) effectively managed, or is it time to consider adding a mast cell stabilizer or a biologic like omalizumab?
3.Am I a candidate for targeted KIT inhibitors like avapritinib or midostaurin?
4.What are the potential side effects of these targeted therapies, and how will we monitor for them?
5.Is hematopoietic stem cell transplantation (HSCT) a consideration for my case now or in the future?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (18)

1
Review and Updates on Systemic Mastocytosis and Related Entities.
Li JY, Ryder CB, Zhang H, et al.
Cancers 2023; (15(23)) doi:10.3390/cancers15235626.
PMID: 38067330
2
New treatments for systemic mastocytosis in 2025.
Costanzo G, Marzio V, Cavaglià E, et al.
Current opinion in allergy and clinical immunology 2025; (25(4)):277-292 doi:10.1097/ACI.0000000000001079.
PMID: 40471046
3
Pathogenesis and Pathology of Mastocytosis.
Metcalfe DD, Mekori YA
Annual review of pathology 2017; (12()):487-514 doi:10.1146/annurev-pathol-052016-100312.
PMID: 28135563
4
Management of indolent mastocytosis and mast cell activation syndrome: A clinical yardstick.
Akin C, Butterfield JH, Castells M, Lyons JJ
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2025; (135(4)):466-477 doi:10.1016/j.anai.2025.06.032.
PMID: 40592381
5
Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes.
González-de-Olano D, Matito A, Orfao A, Escribano L
F1000Research 2016; (5()):2666 doi:10.12688/f1000research.9565.1.
PMID: 27909577
6
Management of Mastocytosis and Mast Cell Activation in Children.
Carter MC, Lange M, Alvarez-Twose I, et al.
The journal of allergy and clinical immunology. In practice 2026; (14(1)):30-42 doi:10.1016/j.jaip.2025.11.016.
PMID: 41285204
7
Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS.
Lemal R, Fouquet G, Terriou L, et al.
The journal of allergy and clinical immunology. In practice 2019; (7(7)):2387-2395.e3 doi:10.1016/j.jaip.2019.03.039.
PMID: 30954641
8
Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications.
Bossi G, Brazzelli V, De Amici M, et al.
Italian journal of pediatrics 2023; (49(1)):6 doi:10.1186/s13052-022-01402-7.
PMID: 36639823
9
Mastocytosis.
Akin C, Arock M, Carter MC, et al.
Nature reviews. Disease primers 2025; (11(1)):30 doi:10.1038/s41572-025-00611-8.
PMID: 40274818
10
Target Therapies for Systemic Mastocytosis: An Update.
Sciumè M, De Magistris C, Galli N, et al.
Pharmaceuticals (Basel, Switzerland) 2022; (15(6)) doi:10.3390/ph15060738.
PMID: 35745657
11
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
DeAngelo DJ, Radia DH, George TI, et al.
Nature medicine 2021; (27(12)):2183-2191 doi:10.1038/s41591-021-01538-9.
PMID: 34873347
12
FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.
Kasamon YL, Ko CW, Subramaniam S, et al.
The oncologist 2018; (23(12)):1511-1519 doi:10.1634/theoncologist.2018-0222.
PMID: 30115735
13
Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Kayser S, Levis MJ, Schlenk RF
Expert review of clinical pharmacology 2017; (10(11)):1177-1189 doi:10.1080/17512433.2017.1387051.
PMID: 28960095
14
Systemic Mastocytosis: Advances in Diagnosis and Current Management.
Pullarkat ST, Wu W, Pullarkat V
Cancer treatment and research 2021; (181()):167-178 doi:10.1007/978-3-030-78311-2_10.
PMID: 34626361
15
Management of Advanced Systemic Mastocytosis: Clinical Challenges.
Tremblay D, Wagner NE, Mascarenhas J
Journal of blood medicine 2024; (15()):421-433 doi:10.2147/JBM.S366367.
PMID: 39279879
16
Management of skeletal-related events and fracture prevention in systemic mastocytosis.
Lunn EM, Lacount S, Greene LW, Asadipooya K
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2026; (37(3)):605-619 doi:10.1007/s00198-025-07726-4.
PMID: 41263967
17
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis.
Zanotti R, Bonifacio M, Lucchini G, et al.
Leukemia 2022; (36(2)):516-524 doi:10.1038/s41375-021-01406-y.
PMID: 34545185
18
Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms.
Tashi T, Deininger MW
Immunology and allergy clinics of North America 2023; (43(4)):723-741 doi:10.1016/j.iac.2023.04.009.
PMID: 37758409

This page provides educational information about standard treatments for systemic mastocytosis. It does not replace professional medical advice; always consult your hematologist or allergist regarding your specific treatment plan.

Get notified when new evidence is published on Systemic mastocytosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents